Get the Weekly Intelligence Brief — top committee picks every Sunday.
ABCL · NASDAQ · STOCK

AbCellera Biologics Inc.

Healthcare Updated August 11, 2026
$9.75
52W $2.75 – $10.29
66/100
$2.98B
-18.1
1.19
AI Committee Verdict
Buy
66/100
Conviction: Moderate · 67% agreement · 6 analysts
Moderate

Is ABCL Bullish or Bearish?

Bullish. Innellis AI committee rates AbCellera Biologics Inc. (ABCL) Buy with a composite score of 66/100 , based on 6 analysts with 67% agreement. Last updated August 11, 2026.

What Would Change This View

Upgrade to Strong Buy
Requires a committee score of 75.0 — +9.14 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Watch
Requires the score to fall below 55.0 — -10.86 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The primary driver is revenue growing 101.3% yoy -- genuine top-line momentum. The main limiting factor is bollinger bandwidth of 77.3% signals elevated volatility. The committee is constructive but not yet at full conviction.

Bull & Bear Case

Bull Case
  • Price-to-book of 1.1x is a discount to asset value — Value
  • Revenue growing 101.3% YoY -- genuine top-line momentum — Growth
  • Price structure making higher highs and higher lows — Technical
  • MACD histogram positive -- bullish momentum — Technical
  • Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
  • Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock — Risk
Bear Case
  • ROE of only -17.5% -- cheap may mean cheap for a reason — Value
  • RSI at 90 is in overbought territory — Technical
  • Price trading above the upper Bollinger Band -- stretched — Technical
  • Bollinger bandwidth of 77.3% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of August 11, 2026
Overall Committee Score
66/100
Agreement
67%
Analysts
6
Conviction
Moderate
Sector Rank
Top 14%
of 192 Healthcare peers
Value Analyst bullish
60 / 100 · Moderate confidence
Classic value case: cheap on multiples with earnings power to back it up
+ Price-to-book of 1.1x is a discount to asset value
− ROE of only -17.5% -- cheap may mean cheap for a reason
Growth Analyst bullish
85 / 100 · Low confidence
Strong, accelerating growth with consistent execution
+ Revenue growing 101.3% YoY -- genuine top-line momentum
Technical Analyst bullish
61 / 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
− RSI at 90 is in overbought territory
Risk Analyst neutral
58 / 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
+ Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock
− Bollinger bandwidth of 77.3% signals elevated volatility
Macro Analyst bullish
78 / 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst neutral
54 / 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager neutral
55 / 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 2 existing position pair(s) are highly correlated already
Open Full Terminal →

Technical Analysis

RSI (14)
90.0
Overbought
MACD Histogram
0.419
Bullish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Mixed
Bollinger %B
1.22
Above Upper Band
Price vs Moving Averages
EMA 9
$7.38 Above
EMA 21
$6.71 Above
EMA 50
$6.21 Above
EMA 200
$4.92 Above

Fundamental Analysis

Valuation
57
Profitability
25
Financial Health
100
Cash Flow
15
Valuation
P/E Ratio -18.1×
P/B Ratio 3.33×
PEG Ratio 33.27
Dividend Yield 0.00%
52W High $10.29
52W Low $2.75
Quality & Growth
ROE -1514.2%
ROA -1079.0%
Gross Margin 7495.2%
Operating Margin -34025.4%
Revenue Growth YoY
Debt / Equity 0.15
AI Fundamental Assessment
[reduced confidence: limited earnings history] P/E ratio of -18.1 (inexpensive relative to a 15-40x range); Price-to-book of 3.3x; PEG ratio of 33.3 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -15.1%; Return on assets of -10.8%; Net margin of -248.8%; Gross margin of 75.0%; Current ratio of 12.77 (healthy short-term liquidity); Debt-to-equity of 0.15; Free cash flow per share is negative (-0.59); Earnings-history trend unavailable; growth based on TTM year-over-year only.
Get the Full ABCL Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →

Explore ABCL Further

📈 Rating History 💰 Earnings 📰 Recent Events 🔄 What Changed 📖 Thesis Evolution 🔍 Similar Stocks
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime